Innoviva Company Profile (NASDAQ:INVA)

About Innoviva

Innoviva logoInnoviva, Inc., formerly Theravance, Inc., focuses on bringing new medicines to patients in areas of unmet need. The Company is engaged in the development, commercialization and financial management of bio-pharmaceuticals. Its portfolio focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol (FF/VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). It operates in providing capital return to stockholders by maximizing the potential value of its respiratory assets partnered with GSK segment. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of VI, a LABA and FF, an inhaled corticosteroid (FF/VI) delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of UMEC, a long-acting muscarinic antagonist (LAMA) and VI, a LABA for the treatment of chronic obstructive pulmonary diseases (COPD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: INVA
  • CUSIP: 88338T10
Key Metrics:
  • Previous Close: $11.38
  • 50 Day Moving Average: $11.99
  • 200 Day Moving Average: $11.87
  • Trailing P/E Ratio: 68.97
  • Foreward P/E Ratio: 9.98
  • P/E Growth: 0.25
  • Market Cap: $1.27B
  • Outstanding Shares: 111,202,000
  • Beta: 1.71
Additional Links:
Companies Related to Innoviva:

Analyst Ratings

Consensus Ratings for Innoviva (NASDAQ:INVA) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $11.60 (1.93% upside)

Analysts' Ratings History for Innoviva (NASDAQ:INVA)
DateFirmActionRatingPrice TargetDetails
7/31/2016Robert W. BairdReiterated RatingNeutral$9.00 -> $11.00View Rating Details
10/29/2015Cowen and CompanyLower Price TargetMarket Perform$15.00 -> $10.00View Rating Details
10/5/2015Morgan StanleyReiterated RatingOverweight$7.00 -> $9.00View Rating Details
9/10/2015Sanford C. BernsteinReiterated RatingMarket Perform$15.00View Rating Details
9/9/2015Bank of America Corp.DowngradeBuy -> Neutral$16.00 -> $13.00View Rating Details
12/2/2014Leerink SwannDowngradeOutperform -> Market Perform$17.00View Rating Details
(Data available from 8/28/2014 forward)


Earnings History for Innoviva (NASDAQ:INVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016Q216$0.11$0.17$31.13 million$32.47 millionViewListenView Earnings Details
4/28/2016Q116$0.09$0.04$28.61 million$24.17 millionViewListenView Earnings Details
2/3/2016Q415$0.01$0.04$20.17 million$22.80 millionViewN/AView Earnings Details
10/28/2015Q315($0.03)($0.04)$15.23 million$13.56 millionViewListenView Earnings Details
7/29/2015Q2($0.06)($0.07)$10.90 million$10.70 millionViewListenView Earnings Details
5/6/2015Q115($0.08)($0.09)$6.80 millionViewListenView Earnings Details
2/18/2015Q414($0.15)($0.14)$5.42 million$7.30 millionViewN/AView Earnings Details
10/30/2014Q314($0.14)($0.19)$6.30 millionViewN/AView Earnings Details
8/18/2014($0.53)($0.18)ViewN/AView Earnings Details
8/6/2014Q214($0.44)($0.57)$4.39 million$0.93 millionViewN/AView Earnings Details
5/6/2014Q114($0.53)($0.62)$4.52 million$0.17 millionViewN/AView Earnings Details
2/6/2014Q413($0.38)($0.46)$6.03 million$1.60 millionViewN/AView Earnings Details
10/24/2013Q313$0.69($0.44)$3.08 million$0.44 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.46)($0.37)$1.43 million$1.33 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.38)($0.39)$2.71 million$1.34 millionViewN/AView Earnings Details
2/12/2013Q4 2012($0.36)($0.33)$3.88 million$5.80 millionViewN/AView Earnings Details
10/30/2012($0.39)($0.37)ViewN/AView Earnings Details
7/31/2012($0.42)($0.42)ViewN/AView Earnings Details
4/26/2012$1.02$0.93ViewN/AView Earnings Details
2/9/2012($0.38)($0.45)ViewN/AView Earnings Details
10/27/2011($0.33)($0.37)ViewN/AView Earnings Details
7/28/2011($0.27)($0.31)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Innoviva (NASDAQ:INVA)
Current Year EPS Consensus Estimate: $0.6 EPS
Next Year EPS Consensus Estimate: $1.14 EPS


Current Dividend Information for Innoviva (NASDAQ:INVA)
Annual Dividend:$0.25
Dividend Yield:2.20%
Payout Ratio:147.07% (Based on Trailing 12 Months of Earnings)
41.67% (Based on Current Year Consensus EPS Estimate)
21.93% (Based on Next Year Consensus EPS Estimate)

Dividend History for Innoviva (NASDAQ:INVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Innoviva (NASDAQ:INVA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2016Eric DesparbesCFOSell3,700$11.77$43,549.00View SEC Filing  
5/18/2016James L TyreeDirectorSell813$10.47$8,512.11View SEC Filing  
5/11/2015Plc GlaxosmithklineMajor ShareholderBuy85,579$1,369,260.00$117,179,901,540.00View SEC Filing  
8/13/2014Junning LeeVPSell53,424$22.50$1,202,040.00View SEC Filing  
8/12/2014Bradford J ShaferSVPSell28,156$22.13$623,092.28View SEC Filing  
8/11/2014Bradford J ShaferSVPSell27,108$22.12$599,628.96View SEC Filing  
9/12/2013Rick WinninghamCEOSell22,353$40.03$894,790.59View SEC Filing  
7/30/2013Mathai MammenSVPSell7,000$36.51$255,570.00View SEC Filing  
6/7/2013Bradford J ShaferSVPSell31,038$35.04$1,087,571.52View SEC Filing  
5/29/2013David L BrinkleyInsiderSell3,808$35.01$133,318.08View SEC Filing  
5/13/2013David L BrinkleyInsiderSell16,129$40.33$650,482.57View SEC Filing  
8/7/2012Michael W AguiarCFOSell60,000$27.04$1,622,400.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Innoviva (NASDAQ:INVA)
DateHeadline logoInnoviva Breaks Below 200-Day Moving Average - Notable for INVA - Nasdaq (NASDAQ:INVA) - August 25 at 5:41 PM logoInnoviva Breaks Below 200-Day Moving Average - Notable for INVA (NASDAQ:INVA) - August 25 at 10:41 AM logoInnoviva Becomes Oversold (INVA) (NASDAQ:INVA) - August 24 at 5:33 PM
News IconStock Gaining Over the Past Six Months: Innoviva, Inc. (:INVA) - Post News (NASDAQ:INVA) - August 22 at 10:14 AM
News IconShares Holding Above Moving Averages: Innoviva, Inc. (:INVA) - Post News (NASDAQ:INVA) - August 19 at 5:40 PM
News IconInstitutions Have Decreased Their Ownership of Innoviva, Inc. (:INVA) - Post News (NASDAQ:INVA) - August 19 at 8:38 AM logo3 Pullback Plays For A Quiet Summer Market (JCP, ADXS) (NASDAQ:INVA) - August 18 at 5:41 PM logoINNOVIVA, INC. Financials (NASDAQ:INVA) - August 12 at 5:45 PM logoOverboarded Directors at Valeant, Yahoo! and Elsewhere Struggle With Activists, M&A (NASDAQ:INVA) - August 12 at 5:45 PM logoETF’s with exposure to Innoviva, Inc. : August 5, 2016 (NASDAQ:INVA) - August 5 at 5:49 PM logoINNOVIVA, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:INVA) - August 5 at 8:41 AM logoInnoviva, Inc. :INVA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016 (NASDAQ:INVA) - August 3 at 5:59 PM logoKeryx (KERX) Stock Down on Wider Q2 Loss, Supply Issues (NASDAQ:INVA) - August 2 at 10:29 AM logoInnoviva: Finally Starting To Gain Some Trust - Seeking Alpha (NASDAQ:INVA) - July 31 at 5:21 PM logoEdited Transcript of INVA earnings conference call or presentation 28-Jul-16 9:00pm GMT (NASDAQ:INVA) - July 29 at 4:20 PM logoInnoviva Reports Second Quarter 2016 Financial Results - Business Wire (press release) (NASDAQ:INVA) - July 29 at 8:37 AM logoInnoviva beats 2Q profit forecasts (NASDAQ:INVA) - July 28 at 6:34 PM logo4:17 pm Innoviva reports EPS in-line, beats on revs (NASDAQ:INVA) - July 28 at 4:17 PM logoINNOVIVA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:INVA) - July 28 at 4:14 PM logoInnoviva Reports Second Quarter 2016 Financial Results (NASDAQ:INVA) - July 28 at 4:05 PM logoVertex (VRTX) Posts Narrower Q2 Loss, Revenues Fall Short - Nasdaq (NASDAQ:INVA) - July 28 at 8:41 AM logoAmgen (AMGN) Tops Q2 Earnings & Revenues, Raises View (NASDAQ:INVA) - July 28 at 8:02 AM logoQ2 2016 Innoviva Inc Earnings Release - After Market Close (NASDAQ:INVA) - July 28 at 7:07 AM
News IconInnoviva, Inc. (NASDAQ:INVA) To Report June 2016 Results - The Voice Registrar (NASDAQ:INVA) - July 27 at 8:28 AM logoAfter GILD Earnings, Which Biomed Stock is Best Right Now? (NASDAQ:INVA) - July 26 at 4:55 PM logoNotable Monday Option Activity: CAVM, INVA, BWLD - Nasdaq (NASDAQ:INVA) - July 26 at 8:37 AM logoShould You Buy Innoviva (INVA) Ahead of Earnings? (NASDAQ:INVA) - July 26 at 8:36 AM logoActelion (ALIOF) Beats Q2 Earnings & Revenues, View Up - Nasdaq (NASDAQ:INVA) - July 24 at 5:20 PM logoSynta (SNTA) Cuts Q2 Loss Y/Y, Madrigal Merger in Focus (NASDAQ:INVA) - July 23 at 9:40 AM logoAegerion to Withdraw Juxtapid from EU, Reduces Workforce - Nasdaq (NASDAQ:INVA) - July 22 at 5:36 PM
News IconEarnings Quick View: Centene Corporation (NYSE:CNC), Terreno Realty Corporation (NYSE:TRNO), Globant S.A. ... - Engelwood Daily (NASDAQ:INVA) - July 22 at 5:36 PM logoSynta (SNTA) Cuts Q2 Loss Y/Y, Madrigal Merger in Focus - Yahoo Finance (NASDAQ:INVA) - July 22 at 5:36 PM
News IconInnoviva, Inc. (NASDAQ:INVA) Upcoming Earnings: What matter for investors? - The Voice Registrar (NASDAQ:INVA) - July 22 at 5:36 PM logoBiogen (BIIB) Stock Up on Q2 Earnings Beat, Raised Outlook (NASDAQ:INVA) - July 21 at 11:42 AM logoInnoviva to Report Second Quarter 2016 Financial Results on July 28 at 5:00 p.m. EDT (NASDAQ:INVA) - July 20 at 4:05 PM logoCelgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma - Nasdaq (NASDAQ:INVA) - July 20 at 3:41 PM logoAstraZeneca's (AZN) Tagrisso Hits Phase III Primary Endpoint - Yahoo Finance (NASDAQ:INVA) - July 20 at 3:41 PM logoEvoke (EVOK) Stock Down on Poor Phase III EVK-001 Data - Nasdaq (NASDAQ:INVA) - July 20 at 8:40 AM logoBristol-Myers' Opdivo Label Expansion Under U.S., EU Review - Nasdaq (NASDAQ:INVA) - July 20 at 8:40 AM logoAstraZeneca's (AZN) Tagrisso Hits Phase III Primary Endpoint - Nasdaq (NASDAQ:INVA) - July 20 at 8:40 AM logoZIOPHARM (ZIOP) Stock Down on Patient Death in Phase I (NASDAQ:INVA) - July 18 at 10:55 AM logoEli Lilly, Boehringer Collaborate for Metastatic Breast Cancer (NASDAQ:INVA) - July 14 at 5:49 PM
News IconWhat's Propelling Innoviva Inc to Increase So Much? - Consumer Eagle (NASDAQ:INVA) - July 14 at 9:11 AM logoCytRx (CYTR) Stock Falls on Unfavorable Aldoxorubicin Data - Nasdaq (NASDAQ:INVA) - July 13 at 8:35 AM
News IconStock Providing Gains on the Month for Investors: Innoviva, Inc. (:INVA) - Telanagana Press (NASDAQ:INVA) - July 13 at 8:35 AM logoGilead's Pan-Genotypic HCV Drug Epclusa Gains EU Approval - Yahoo Finance (NASDAQ:INVA) - July 12 at 5:55 PM logoLigand (LGND) Signs Deal with Gilead for OmniAb Technology - Yahoo Finance (NASDAQ:INVA) - July 12 at 5:55 PM logoSeth Klarman Buys —5 Million Shares of Cascadian Therapeutics - (NASDAQ:INVA) - July 12 at 5:55 PM logoAbbVie's ABT-414 Gets Rare Pediatric Disease Status in U.S. - Nasdaq (NASDAQ:INVA) - July 12 at 5:55 PM logoAbbVie's ABT-414 Gets Rare Pediatric Disease Status in U.S. (NASDAQ:INVA) - July 12 at 10:02 AM


Innoviva (NASDAQ:INVA) Chart for Sunday, August, 28, 2016

Last Updated on 8/28/2016 by Staff